{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:29:31Z","timestamp":1778509771106,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"DOI":"10.7759\/cureus.108646","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:18:13Z","timestamp":1778505493000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use and Blood Pressure Levels in Nondiabetic Obese Adults: A Cross-Sectional Analysis"],"prefix":"10.7759","author":[{"given":"Moses C","family":"Odoeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Okwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekapong","family":"Bassey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinyele","family":"Oladimeji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thy-Will D","family":"Aboflah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Adelola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael O","family":"Ewejobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nnaemeka H","family":"Ugwuchukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daad G","family":"Alrowaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okelue E","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20761","article-title":"Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999-2010","volume":"22","author":"Saydah S","year":"2014","unstructured":"Saydah S, Bullard KM, Cheng Y, Ali MK, Gregg EW, Geiss L, Imperatore G. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999-2010. Obesity (Silver Spring). 2014, 22:1888-95. 10.1002\/oby.20761","journal-title":"Obesity (Silver Spring)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003619","article-title":"Trends in cardiovascular health metrics in obese adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014","volume":"5","author":"Guo F","year":"2016","unstructured":"Guo F, Garvey WT. Trends in cardiovascular health metrics in obese adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. J Am Heart Assoc. 2016, 5:10.1161\/JAHA.116.003619","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003072","article-title":"BMI and blood pressure control among United States adults with hypertension","volume":"40","author":"Foti K","year":"2022","unstructured":"Foti K, Hardy ST, Chang AR, Selvin E, Coresh J, Muntner P. BMI and blood pressure control among United States adults with hypertension. J Hypertens. 2022, 40:741-8. 10.1097\/HJH.0000000000003072","journal-title":"J Hypertens"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3203","article-title":"Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology\/American Heart Association Hypertension Guideline","volume":"168","author":"Carey RM","year":"2018","unstructured":"Carey RM, Whelton PK. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology\/American Heart Association Hypertension Guideline. Ann Intern Med. 2018, 168:351-8. 10.7326\/M17-3203","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf035","article-title":"Mechanisms and treatment of obesity-related hypertension\u2014part 2: treatments","volume":"18","author":"Parvanova A","year":"2025","unstructured":"Parvanova A, Abbate M, Reseghetti E, Ruggenenti P. Mechanisms and treatment of obesity-related hypertension\u2014part 2: treatments. Clin Kidney J. 2025, 18:sfaf035. 10.1093\/ckj\/sfaf035","journal-title":"Clin Kidney J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90054","article-title":"Trends in glucagon-like peptide-1 agonist use and BMI among obese adults with type 2 diabetes: analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), adjusted for cardiovascular comorbidity","volume":"17","author":"Eneh V","year":"2025","unstructured":"Eneh V, Chatelain NF, Okobi OE, et al.. Trends in glucagon-like peptide-1 agonist use and BMI among obese adults with type 2 diabetes: analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), adjusted for cardiovascular comorbidity. Cureus. 2025, 17:e90054. 10.7759\/cureus.90054","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025, 138:934-40. 10.1016\/j.amjmed.2025.01.021","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari M","year":"2023","unstructured":"Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes. 2023, 16:575-95. 10.2147\/DMSO.S387116","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma X","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, et al.. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021, 17:2050-68. 10.7150\/ijbs.59965","journal-title":"Int J Biol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70012","article-title":"Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: a systematic review and network meta-analysis","volume":"15","author":"Ali A","year":"2025","unstructured":"Ali A, Siddiqui AA, Usman MS, Shahid I, Khan MS, Perswani P. Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: a systematic review and network meta-analysis. Clin Obes. 2025, 15:e70012. 10.1111\/cob.70012","journal-title":"Clin Obes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91722","article-title":"GLP-1 agonists and cardiovascular risk markers in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011-2018","volume":"17","author":"Telakeng Tekengne BO","year":"2025","unstructured":"Telakeng Tekengne BO, Eke CI, Cumaaran C, et al.. GLP-1 agonists and cardiovascular risk markers in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011-2018. Cureus. 2025, 17:e91722. 10.7759\/cureus.91722","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018, 34:575-84. 10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95938","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in obese patients without diabetes: a systematic review and meta-analysis","volume":"17","author":"Mohamed Ali Elbashir R","year":"2025","unstructured":"Mohamed Ali Elbashir R, Elbashir A, Urimuke Basake R, et al.. Glucagon-like peptide-1 (GLP-1) receptor agonists in obese patients without diabetes: a systematic review and meta-analysis. Cureus. 2025, 17:e95938. 10.7759\/cureus.95938","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012305","article-title":"Hypertension related to obesity: pathogenesis, characteristics and factors for control","volume":"23","author":"El Meouchy P","year":"2022","unstructured":"El Meouchy P, Wahoud M, Allam S, Chedid R, Karam W, Karam S. Hypertension related to obesity: pathogenesis, characteristics and factors for control. Int J Mol Sci. 2022, 23:12305. 10.3390\/ijms232012305","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13518","article-title":"Pathophysiology and treatment of obesity-related hypertension","volume":"21","author":"Chrysant SG","year":"2019","unstructured":"Chrysant SG. Pathophysiology and treatment of obesity-related hypertension. J Clin Hypertens (Greenwich). 2019, 21:555-9. 10.1111\/jch.13518","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90964","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonist use and inflammatory markers among U.S. Adults: a National Health and Nutrition Examination Survey (NHANES)-based analysis","volume":"17","author":"Youkhana S","year":"2025","unstructured":"Youkhana S, Odusanmi SS, Ihuchukwu BK, et al.. Glucagon-like peptide-1 (GLP-1) receptor agonist use and inflammatory markers among U.S. Adults: a National Health and Nutrition Examination Survey (NHANES)-based analysis. Cureus. 2025, 17:e90964. 10.7759\/cureus.90964","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004871","article-title":"Glucagon-like peptide-1 receptor agonists for obesity: growing popularity met with growing questions over safety","volume":"23","author":"Chao AM","year":"2026","unstructured":"Chao AM, Gilden A, Wadden TA. Glucagon-like peptide-1 receptor agonists for obesity: growing popularity met with growing questions over safety. PLoS Med. 2026, 23:e1004871. 10.1371\/journal.pmed.1004871","journal-title":"PLoS Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27 Suppl 2","author":"Thomsen RW","year":"2025","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025, 27 Suppl 2:66-88. 10.1111\/dom.16364","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.20900","article-title":"Hypertension statistics for US adults: an open-source web application for analysis and visualization of National Health and Nutrition Examination Survey data","volume":"80","author":"Jaeger BC","year":"2023","unstructured":"Jaeger BC, Chen L, Foti K, et al.. Hypertension statistics for US adults: an open-source web application for analysis and visualization of National Health and Nutrition Examination Survey data. Hypertension. 2023, 80:1311-20. 10.1161\/HYPERTENSIONAHA.123.20900","journal-title":"Hypertension"},{"key":"ref20","unstructured":"National Health and Nutrition Examination Survey (NHANES). Accessed. April 3, 2026: https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/search\/default.aspx."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/489070-association-between-glucagon-like-peptide-1-glp-1-receptor-agonist-use-and-blood-pressure-levels-in-nondiabetic-obese-adults-a-cross-sectional-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:18:16Z","timestamp":1778505496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/489070-association-between-glucagon-like-peptide-1-glp-1-receptor-agonist-use-and-blood-pressure-levels-in-nondiabetic-obese-adults-a-cross-sectional-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.108646","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}